Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04263181 · ClinicalTrials.gov registry record

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

A clinical trial of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Washington University School of Medicine.

Active
Registry status
80
Enrollment target
1
Study location

NCT04263181: Active study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Washington University School of Medicine.

NCT04263181 is a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 80 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04263181, a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Washington University School of Medicine.

ACTIVE NOT RECRUITING
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

In this study, the investigators will explore the feasibility of ex vivo drug screening to predict sensitivity to chemotherapy resistance and to identify novel synergy between chemotherapies.

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndromes

Interventions

  • PROCEDURE Peripheral blood draw
  • PROCEDURE Bone marrow aspirate
  • PROCEDURE Buccal swab

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2020-01-29
Est. Completion 2027-01-31
Washington University School of Medicine

1,502 total trials

What the registry record for NCT04263181 still lists

NCT04263181 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (31% lower).

The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Peripheral blood draw is the first listed.

NCT04263181 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT04263181 about?

NCT04263181 is a clinical study titled "AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration". In this study, the investigators will explore the feasibility of ex vivo drug screening to predict sensitivity to chemotherapy resistance and to identify novel synergy between chemotherapies.

What is the current status of trial NCT04263181?

This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2020-01-29. Estimated completion is 2027-01-31.

What conditions does trial NCT04263181 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes.

What interventions are being tested in trial NCT04263181?

The interventions under investigation include: Peripheral blood draw (PROCEDURE), Bone marrow aspirate (PROCEDURE), Buccal swab (PROCEDURE).

Who is sponsoring clinical trial NCT04263181?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04263181 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04263181's enrollment target sits among peer trials

80 97th of 306 higher than 206 of 306 other Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04263181, the US trial registry maintained by the National Library of Medicine. NCT04263181 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.